A Phase 3 interventional study of Placebo and pregabalin in Restless Legs Syndrome, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-22.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess efficacy and safety of pregabalin in treating moderate to severe Restless Legs Syndrome in comparison to placebo.
259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.
Browse Restless Legs Syndrome studies →Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
First submitted before Pfizer's Upjohn has merged with Mylan to form Viatris Inc. became part of Viatris Inc..
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Placebo
Drug: pregabalin
Drug: pregabalin
Placebo, orally administered once a day, 1-3 hours before bedtime for 12 weeks
pregabalin 150 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 weeks
Also known as: Lyrica
pregabalin 300 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 weeks
Also known as: Lyrica
Changes from baseline in RLS symptom severity using the International Restless Leg Group Rating Scale (IRLS) total score for efficacy assessment
Time frame: up to 12 weeks
The proportion of subjects responding to treatment using the Clinical Global Impression - Improvement (CGI-I) scale for efficacy assessment
Time frame: up to 12 weeks
Subjective Sleep Questionnaire (SSQ - Subjective WASO)
Time frame: up to 12 weeks
RLS Next Day Impact (RLS-NDI)
Time frame: up to 12 weeks
Limb pain rating using a numerical rating scale (Limb Pain - NRS)
Time frame: up to 12 weeks
Clinical Global Impressions - Severity (CGI-S)
Time frame: up to 12 weeks
Medical Outcomes Study - Sleep Scale (MOS - SS)
Time frame: up to 12 weeks
Impact on Life (IRLS symptom impact sub-score)
Time frame: up to 12 weeks
RLS-Quality of Life Scale (RLS-QoL)
Time frame: up to 12 weeks
Medical Outcomes Study - Short Form 36 (SF-36)
Time frame: up to 12 weeks
Work Productivity and Activity Impairment - Specific Health Problem (WPAI-SHP)
Time frame: up to 12 weeks
Profile of Mood States (POMS)
Time frame: up to 12 weeks
Adverse events from spontaneous reports will be monitored throughout the trial and summarized by treatment group
Time frame: up to 12 weeks
Sheehan Suicidality Tracking Scale (S-STS) will be utilized to assess the risk of suicide
Time frame: up to 12 weeks
Changes in RLS symptoms following the discontinuation of study drug at the end of treatment will be evaluated by collection of the IRLS scores at the end of the drug taper period at Week 13
Time frame: week 13
No study locations are listed for this record.
The record gives a start of May 2010, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →